Training the Next Generation of Innovators in Dermatology

Shuai Xu, James Allred, Brandon Kirsch, Adam Raff, R. Rox Anderson, William Ju

Since the 1950s, the number of new drugs approved by the Food and Drug Administration per $1 billion invested in research and development has fallen 80-fold (Scannell et al., 2012).

Dermatology is not immune to this trend. Topical drug innovation has fallen by 45% from 2000 to 2004 compared with 2010 to 2014 with the majority of approvals constituting dosage form changes (Walter and Xu, 2015). Certainly, there have been impressive drug developments for melanoma and psoriasis over the last decade.

Source: Full Article | JID, November 2016, Volume 136, Issue 11, Pages 2113–2115 .

Download PDF